샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514001

세계의 H1N1 백신 시장

H1N1 Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 268 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 H1N1 백신 시장은 2030년까지 32억 달러에 이를 것으로 예상

2023년에 22억 달러로 평가된 세계의 H1N1 백신 시장은 분석 기간 2023년부터 2030년까지 CAGR 5.4%로 성장할 전망이며, 2030년에는 32억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 근육내 백신은 CAGR 6.5%로 성장을 지속하고, 분석 기간 종료 시 11억 달러에 도달할 것으로 예측됩니다. 비강 백신 분야의 성장률은 분석 기간 동안 CAGR 5.6%로 추정됩니다.

미국 시장은 5억 7,260만 달러로 추정, 중국은 CAGR 8.5%로 성장 예측

미국의 H1N1 백신 시장은 2023년 5억 7,260만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 7억 3,450만 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 8.5%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.0%와 4.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.8%로 성장할 것으로 예측됩니다.

H1N1 백신-주요 동향 및 촉진요인

H1N1 백신은 일반적으로 돼지 인플루엔자로 알려진 H1N1 인플루엔자 바이러스의 확산을 막는 데 매우 중요합니다. H1N1 바이러스는 2009년에 처음으로 출현하였으며 세계적인 유행을 일으켜 효과적인 백신 전략의 필요성을 부각시켰습니다. 이러한 백신은 불활성화(죽음) 바이러스, 약독화(생) 바이러스, 재조합 기술 등 다양한 방법으로 개발되고 있습니다. 이 백신은 면역계를 자극하고 H1N1 바이러스를 인식하고 싸우는 것으로 질병의 중증도와 발병률을 낮추기 위해 고안되었습니다. 특히 인플루엔자의 유행기에는 소아, 노인, 임신한 여성, 기초 질환을 가진 사람 등 위험이 높은 그룹을 대상으로 매년 백신 접종 캠페인을 실시하고 공중 보건에 중요한 역할을 수행하고 있습니다. 바이러스의 지속적인 진화로 인해 신형에 대한 백신의 효능을 보장하기 위해 백신 제형의 지속적인 업데이트 및 개선이 필요합니다.

기술의 발전은 H1N1 백신의 개발, 제조 및 유통을 현저하게 향상시켰습니다. 세포 기반 기술과 재조합 DNA 기술을 포함한 최신 제조 기술은 백신 생산의 효율성과 속도를 향상시켰습니다. 이러한 방법은 아웃 브레이크에 대응한 신속한 확장성을 가능하게 하여, 세계 수요를 만족시키는 충분한 공급이 확보되게 되었습니다. 또한 면역반응을 높이기 위해 백신에 첨가되는 물질인 보조제 기술의 진보로 H1N1 백신의 효능이 향상되고 있습니다. 감시 시스템의 강화와 보건 기관 간의 세계적인 협력은 바이러스 돌연변이의 적시 식별을 용이하게 하여 최신 백신의 개발을 가능하게 했습니다. 또한, 전자 의료 기록(EHR) 및 모바일 건강 앱과 같은 디지털 건강 도구의 통합은 백신 접종 프로그램의 효과적인 모니터링 및 관리를 지원하며, 높은 접종률과 백신 효능의 더 나은 추적을 보장합니다.

H1N1 백신 시장의 성장은 백신 접종의 중요성에 대한 인식을 높이고, 정부의 이니셔티브와 자금 제공, 백신 개발의 기술 진보 등 여러 요인에 의해 야기됩니다. 예방 접종의 이점을 강조하는 공중 보건 캠페인은 예방 섭취를 크게 증가 시켰습니다. 백신의 연구개발 및 유통에 자금과 자원을 제공하는 정부의 프로그램과 정책도 시장 성장에 있어 매우 중요한 역할을 합니다. 생명공학과 면역학의 기술적 진보로 더욱 효과적이고 안전한 백신이 개발되고 있습니다. 또한, 인플루엔자 유행 증가와 H1N1 바이러스의 지속적인 돌연변이는 지속적인 예방 접종의 필요성을 높입니다. 제약회사와 연구기관의 협력으로 백신의 혁신과 입수가 가속화되고 있습니다. 세계의 건강 관리 인프라 확장과 콜드체인 물류 개선은 H1N1 백신의 광범위한 배포와 가용성을 더욱 강화하고 있습니다. 전반적으로 이러한 요인은 H1N1 백신 시장의 견조한 성장과 개척에 기여합니다.

조사 대상 기업 예(주목의 33사)

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global H1N1 Vaccines Market to Reach US$3.2 Billion by 2030

The global market for H1N1 Vaccines estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Intramuscular Vaccines, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Intranasal Vaccines segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$572.6 Million While China is Forecast to Grow at 8.5% CAGR

The H1N1 Vaccines market in the U.S. is estimated at US$572.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$734.5 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

H1N1 Vaccines - Key Trends and Drivers

H1N1 vaccines are critical in preventing the spread of the H1N1 influenza virus, commonly known as swine flu. The H1N1 virus first emerged in 2009, causing a global pandemic that highlighted the need for effective vaccination strategies. These vaccines are developed using various methods, including inactivated (killed) virus, live attenuated (weakened) virus, and recombinant technologies. They are designed to stimulate the immune system to recognize and combat the H1N1 virus, thereby reducing the severity and incidence of the disease. Annual vaccination campaigns, particularly during flu season, play a crucial role in public health initiatives, targeting high-risk groups such as children, the elderly, pregnant women, and individuals with underlying health conditions. The ongoing evolution of the virus necessitates continuous updates and improvements in vaccine formulations to ensure their effectiveness against new strains.

Technological advancements have significantly enhanced the development, production, and distribution of H1N1 vaccines. Modern manufacturing techniques, including cell-based and recombinant DNA technologies, have improved the efficiency and speed of vaccine production. These methods allow for rapid scalability in response to outbreaks, ensuring sufficient supply to meet global demand. Additionally, advancements in adjuvant technology, which are substances added to vaccines to boost the immune response, have improved the efficacy of H1N1 vaccines. Enhanced surveillance systems and global collaboration among health organizations facilitate the timely identification of viral mutations, enabling the development of updated vaccines. Moreover, the integration of digital health tools, such as electronic health records (EHRs) and mobile health apps, supports effective monitoring and management of vaccination programs, ensuring higher coverage rates and better tracking of vaccine efficacy.

The growth in the H1N1 vaccines market is driven by several factors, including increasing awareness of the importance of vaccination, government initiatives and funding, and technological advancements in vaccine development. Public health campaigns emphasizing the benefits of vaccination have significantly increased vaccine uptake. Government programs and policies that provide funding and resources for vaccine research, development, and distribution also play a pivotal role in market growth. Technological advancements in biotechnology and immunology have led to the development of more effective and safer vaccines. Additionally, the rising prevalence of influenza outbreaks and the continuous mutation of the H1N1 virus drive the need for ongoing vaccination efforts. Collaboration between pharmaceutical companies and research institutions accelerates the innovation and availability of vaccines. The expansion of global healthcare infrastructure and improvements in cold chain logistics further support the widespread distribution and accessibility of H1N1 vaccines. Overall, these factors collectively contribute to the robust growth and development of the H1N1 vaccines market.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Vaccination Importance Throws the Spotlight on H1N1 Vaccines
    • Government Initiatives and Funding Propel Growth in Vaccine Research and Development
    • Technological Advancements in Biotechnology Expands Addressable Market Opportunity
    • Enhanced Surveillance Systems Strengthens Business Case for Timely Vaccine Updates
    • Integration of Adjuvant Technology Generates Demand for More Effective Vaccines
    • Development of Cell-Based and Recombinant DNA Technologies Drives Adoption of Modern Manufacturing Methods
    • Increasing Influenza Outbreaks and Viral Mutations Accelerates Demand for H1N1 Vaccines
    • Digital Health Tools and EHRs Spur Growth in Vaccination Program Management
    • Improvements in Cold Chain Logistics Sustains Growth in Vaccine Accessibility
    • Public Health Campaigns and Education Programs Generates Awareness and Vaccine Uptake
    • Ongoing Research in Immunology and Virology Expands Addressable Market Opportunity for Advanced Vaccines
    • Impact of Seasonal Variability on Vaccination Needs
    • Safety and Efficacy Improvements in Vaccine Formulations Drives Adoption of New Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World H1N1 Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • JAPAN
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Japan 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • CHINA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: China 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • EUROPE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Europe 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • FRANCE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: France 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • GERMANY
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Italy 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • UNITED KINGDOM
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: UK 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Spain 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Russia 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ASIA-PACIFIC
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • AUSTRALIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Australia 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • INDIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: India 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: South Korea 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • LATIN AMERICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Latin America 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Latin America 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Argentina 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Brazil 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Mexico 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • MIDDLE EAST
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Middle East 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Middle East 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Iran 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Israel 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UAE 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • AFRICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Africa 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제